[1]
|
庄 辉. ALD 的流行病学[J]. 中华肝脏病杂志, 2003, 11: 698. |
[2]
|
全国酒精性肝病调查协作组. 全国酒精性肝病的多中心调查分析[J]. 中华消化杂志 2007; 27: 231. |
[3]
|
中国药典[M]. 2005版1部. 2005: 364. |
[4]
|
Chen ML, Tsai SH, Ip SP, et al. Long-term treatment with a "Yang-Invigorating" Chinese herbal formula, WuZi-YanZongWan, reduces mortality and liver oxidative damage in chronic alcohol-Intoxicated rats[J]. Rejuv Res, 2010, 13: 459. |
[5]
|
Chen ML, Ip SP, Tsai SH, et al. Biochemical mechanism of Wu-Zi-Yan-Zong-Wan, a traditional Chinese herbal formula, against alcohol-induced oxidative damage in CYP2E1 cDNA-transfected HepG2 (E47) cells[J]. J Ethnopharmacol, 2010, 128: 116. |
[6]
|
Ronis MJ, Hakkak R, Korourian S, et al. Alcoholic liver disease in rats fed ethanol as part of oral or intragastric low-carbohydrate liquid diets[J]. Exp Biol Med 2004; 229: 351. |
[7]
|
Albano E. New concepts in the pathogenesis of alcoholic liver disease[J]. Expert Rev Gastroenterol Hepatol 2008; 2:749. |
[8]
|
Arteel GE. Oxidants and antioxidants in chronic alcoholic liver disease[J]. Gastroenterology, 2003, 124: 778. |
[9]
|
Hanck C, Rossol S, Bocker U, et al. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis[J]. Alcohol Alcoholism, 1998, 33:606. |
[10]
|
Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases[J]. Gastroenterology, 1992, 103: 264. |
[11]
|
Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-α monoclonal antibody therapy in severe alcoholic hepatitis[J]. J Hepatol, 2003, 38: 419. |
[12]
|
Menon K, Stadheim L, Kamath P, et al. Safety and tolerability of etanercept in patients with alcoholic hepatitis[J]. Am J Gastroenterol, 2004, 99: 255. |
[13]
|
Spahr L, Rubbia-Brandt L, Frossard J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study[J]. J Hepatol, 2002, 37: 448. |